Nowadays, cancer treatment has entered the era of personalized and precision medicine.[39, 40, 41] Our study revealed that endocrine‐resistant breast cancer patients with p‐AKT1high and nuclear IRF3low by immunohistochemistry might be a suitable population to receive a combination regimen of AKT inhibitors and STING agonists. This evidence concerns the gene AKT1 and breast carcinoma.